Women's Health Issues
Volume 19, Issue 3 , Pages 211-219 , May 2009

Treatment of Anemia among Women with Chronic Kidney Disease in United States Outpatient Settings

  • Rafia S. Rasu, PhD

      Affiliations

    • School of Pharmacy, University of Missouri—Kansas City, Kansas City, Missouri
    • Corresponding Author InformationCorrespondence to: Rafia S. Rasu, PhD, Assistant Professor of Pharmacy Practice, School of Pharmacy, University of Missouri-Kansas City, 4247 Health Sciences Building, 2464 Charlotte Street, Kansas City, MO 64108.
    • ,
  • Sujata S. Jayawant, PhD

      Affiliations

    • Analysis Group, Inc., Boston, Massachusetts
    • ,
  • Madison Abercrombie

      Affiliations

    • School of Nursing, University of Missouri—Kansas City, Kansas City, Missouri
    • ,
  • Rajesh Balkrishnan, PhD

      Affiliations

    • Colleges of Pharmacy and Public Health, Columbus, Ohio

Received 23 May 2008 ,Revised 18 January 2009 ,Accepted 16 March 2009.

References 

  1. Alexander M, Kewalramani R, Agodoa I, Globe D. Association of anemia correction with health related quality of life in patients not on dialysis. Current Medical Research and Opinion. 2007;23:1997–3008
  2. Arora P, Obrador GT, Ruthazer R, Kausz AT, Meyer KB, Jenuleson CS, et al. Prevalence, predictors, and consequences of late nephrology referral at a tertiary care center. Journal of the American Society of Nephrology. 1999;10:1281–1286
  3. Bailie GR, Eisele G, Liu L, Roys E, Kiser M, Finkelstein F, et al. Pattern of medication use in the RRI-CKD study: Focus on medications with cardiovascular effects. Nephrology, Dialysis, Transplantation. 2005;20:1110–1115
  4. Bailie GR, Uhlig K, Levey AS. Clinical practice guidelines in nephrology: Evaluation, classification, and stratification of chronic kidney disease. Pharmacotherapy. 2005;25:491–502
  5. Balkrishnan R, Cook JM, Shaffer MP, Saltzberg FB, Feldman SR, Fleischer AB. Analysis of factors associated with prescription of a potentially inappropriate combination dermatological medication among US outpatient physicians. Pharmacoepidemiology and Drug Safety. 2004;13:133–138
  6. Balkrishnan R, Rasu RS, Rajagopalan R. Physician and patient determinants of pharmacologic treatment of sleep difficulties in outpatient settings in the United States. Sleep. 2005;28:715–719
  7. Campoy S, Elwell R. Pharmacology & CKD: How chronic kidney disease and its complications alter drug response. American Journal of Nursing. 2005;105:60–71quiz 72
  8. Collins A. Anemia management prior to dialysis: Cardiovascular and cost-benefit observations. Nephrology Dialysis Transplantation. 2003;18(Suppl 2):ii2–ii6
  9. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. American Journal of Kidney Diseases. 2003;41:1–12
  10. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, et al. Prevalence of chronic kidney disease in the United States. Journal of the American Medical Association. 2007;298:2038–2047
  11. Eriksen BO, Ingebretsen OC. The progression of chronic kidney disease: A 10-year population-based study of the effects of gender and age. Kidney International. 2006;69:375–382
  12. Fields L, Burt V, Cutler J, Hughes J, Rocella E, Sorlie P. The burden of adult hypertension in the United States, 1988–2000. Journal of the American Medical Association. 2003;292:199–206
  13. Franconi F, Brunelleschi S, Steardo L, Cuomo V. Gender differences in drug responses. Pharmacological Research. 2007;55:81–95
  14. Gregg EW, Cheng YJ, Cadwell BL, Imperatore G, Williams DE, Flegal KM, et al. Secular trends in cardiovascular disease risk factors according to body mass index in US adults. Journal of the American Medical Association. 2005;293:1868–1874
  15. Kovesdy CP, Trivedi BK, Kalantar-Zadeh K, Anderson JE. Association of anemia with outcomes in men with moderate and severe chronic kidney disease. Kidney International. 2006;69:560–564
  16. Lee E. Analyzing complex survey data. 2nd ed.. Thousand Oaks, CA: Sage Publications; 2006;
  17. Leendertse AJ, Egberts AC, Stoker LJ, van den Bemt PM HARM Study Group. Frequency of and risk factors for preventable medication-related hospital admissions in the Netherlands. Archives of Internal Medicine. 2008;168:1890–1896
  18. Levin A, Thompson CR, Ethier J, Carlisle EJ, Tobe S, Mendelssohn D, et al. Left ventricular mass index increase in early renal disease: Impact of decline in hemoglobin. American Journal of Kidney Disease. 1999;34:125–134
  19. Maddux FW, Shetty S, del Aguila MA, Nelson MA, Murray BM. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease. The Annals of Pharmacotherapy. 2007;41:1761
  20. McCarley P. The KDOQI clinical practice guidelines and clinical practice recommendations for treating anemia in patients with chronic kidney disease: Implications for nurses. Nephrology Nursing Journal: Journal of the American Nephrology Nurses' Association. 2006;33:423–426
  21. McClellan W, Aronoff SL, Bolton WK, Hood S, Lorber DL, Tang KL, et al. The prevalence of anemia in patients with chronic kidney disease. Current Medical Research & Opinion. 2004;20:1501–1510
  22. Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. Journal of the American Medical Association. 2003;289:76–79
  23. Moses, S. (2008, January 13). Family practice notebook: Polypharmacy. Available: http://www.fpnotebook.com/GER10.htm. Accessed February 14, 2008.
  24. National Center for Health Statistics (NCHS). (2006, November 10). Ambulatory Health Care Data. NAMCS description. Available: http://www.cdc.gov/nchs/about/major/ahcd/ahcd1.htm. Accessed November 10, 2007.
  25. National Kidney Foundation (NKF) . K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. American Journal of Kidney Diseases. 2002;39(2 Suppl. 1):S1–S266
  26. National Kidney Foundation (NKF) . K/DOQI clinical practice guidelines for anemia of chronic kidney disease. American Journal of Kidney Diseases. 2006;47:S17–S132
  27. National Kidney Foundation (NKF). (2006b). The National Kidney Foundation kidney disease outcomes quality initiative (NKF KDOQI). Available: http://www.kidney.org/professionals/KDOQI/. Accessed November 10, 2007.
  28. Ofsthun N, Labrecque J, Lacson E, Keen M, Lazarus JM. The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patients. Kidney International. 2003;63:1908–1914
  29. Patel HR, Pruchnicki MC, Hall LE. Assessment for chronic kidney disease service in high-risk patients at community health clinics. Annals of Pharmacotherapy. 2005;39:22–27
  30. Perkins R, Olson S, Hansen J, Lee J, Stiles K, Lebrun C. Impact of an anemia clinic on emergency room visits and hospitalizations in patients with anemia of CKD pre-dialysis. Nephrology Nursing Journal. 2007;34:167–182
  31. Rasu RS, Crawford T, Manley H, Balkrishnan R. Treatment and costs associated with anemic chronic kidney disease patients. Current Medical Research and Opinion. 2008;24:129–137
  32. Rasu RS, Manley HJ, Crawford T, Balkrishnan R. Undertreatment of anemia in patients with chronic kidney disease in the United States: Analysis of national outpatient survey data. Clinical Therapeutics. 2007;29:1524–1534
  33. Ryan TP, Sloand JA, Winters PC, Corsetti JP, Fisher SG. Chronic kidney disease prevalence and rate of diagnosis. American Journal of Medicine. 2007;120:981–986
  34. Santoro A, Canova C. Anemia and erythropoietin treatment in chronic kidney diseases. Minerva Uroligica Nefrologica. 2005;57:23–31
  35. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Hypertension. 2003;42:1050–1065
  36. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, et al. Correction of anemia with epoetin alfa in chronic kidney disease [see comment]. New England Journal of Medicine. 2006;355:2085–2098
  37. Smith DH, Gullion CM, Nichols G, Keith DS, Brown JB. Cost of medical care for chronic kidney disease and comorbidity among enrollees in a large HMO population [see comment]. Journal of the American Society of Nephrology. 2004;15:1300–1306
  38. St. Peter W. Collaborative anemia management in chronic kidney disease patients: A pharmacist's viewpoint. Medscape Nephrology. 2006;3(2):
  39. Stevens LA. Toward optimal health: Lesley A. Stevens, M.D. discusses issues of chronic kidney disease in women. Interview by Jodi R. Godfrey. Journal of Women's Health. 2006;15:123–126
  40. National Institutes of Health. (2007). Healthy people 2010 chronic kidney disease objectives. Available: http://www2.niddk.nih.gov/AboutNIDDK/ReportsAndStrategicPlanning/Healthy_People_2010_Kidney_Disease.htm. Accessed February 15, 2008.
  41. Tran C, Knowles SR, Liu BA, Shear NH. Gender differences in adverse drug reactions. The Journal of Clinical Pharmacology. 1998;38:1003–1009
  42. U.S. Department of Health and Human Services: Health Resources and Services Administration. (2003). Changing demographics: Implications for physicians, nurses, and other health workers. Available: http://bhpr.hrsa.gov/healthworkforce/reports/changedemo/Content.htm. Accessed February 15, 2008.
  43. U.S. Food and Drug Administration (FDA). (2008). Information on Erythropoiesis-Stimulating Agents (ESAs): Epoetin alfa (marketed as Procrit, Epogen) Darbepoetin alfa (marketed as Aranesp). Available: http://www.fda.gov/cder/drug/infopage/RHE/default.htm. Accessed December 19, 2008.
  44. United States Renal Data System (USRDS) . USRDS 2005 annual data report: Atlas of end-stage renal disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2006;
  45. United States Renal Data Systems (USRDS) . USRDS 2006 annual data report: Atlas of end-stage renal disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2007;
  46. Wish J, Coyne DW. Use of erythropoiesis-stimulating agents in patients with anemia of chronic kidney disease: Overcoming the pharmacological and pharmacoeconomic limitations of existing therapies. Mayo Clinic Proceedings. 2007;82:1371–1380

PII: S1049-3867(09)00028-0

doi: 10.1016/j.whi.2009.03.003

Women's Health Issues
Volume 19, Issue 3 , Pages 211-219 , May 2009

Article Tools